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aneurysms. For example, autogenous bypass grafts per-
formed for popliteal aneurysmal disease tend to dilate over
time as compared with vein grafts for occlusive disease that
do not.4 In this regard, vein graft aneurysms arose in 10
of 24 patients (42%) with arterial aneurysms in contrast to
four of 221 patients (0.02%) who underwent treatment
for occlusive disease (P < .001).5 It is uncertain whether
such changes are structural in character or are the result of
differences in vasoactive substances.
This investigation was designed to determine whether
differences existed in brachial artery vascular reactivity in
patients with AAAs in comparison with those with occlu-
sive vascular disease and healthy control subjects and, if
differences existed, whether they reflected differences in
known mediators of vasomotion.
METHODS
Patient selection. Eleven patients with AAAs, nine
patients with peripheral arterial occlusive disease (PAOD),
and 10 individuals without vascular disease were studied.
The subjects were all male, nondiabetic, nonsmokers and
ranged in age from 44 to 85 years. Cardiovascular risk fac-
Patients with abdominal aortic aneurysms (AAAs) are
known to be at risk for the development of femoral and
popliteal artery aneurysms, which suggests the existence of
a generalized disease process.1-3 Furthermore, insight into
aneurysmal disease may be forthcoming from observations
of vein grafts placed in patients with and without arterial
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Objective: This investigation was designed to determine whether differences in vasoreactivity occur in patients with
abdominal aortic aneurysms (AAAs) as compared with patients with peripheral arterial occlusive disease (PAOD) or
individuals (controls) without known vascular disease.
Methods: Brachial artery vasoreactivity was assessed in a blinded fashion, after endothelium-dependent (ED) and
endothelium-independent (EI) flow-mediated vasodilation, in age-matched, male patients with AAAs (n = 11) or
PAOD (n = 9) or in controls (n = 10). There were no significant differences in prestudy systolic or diastolic blood pres-
sure, body mass index, or antilipidemic medications among the groups studied. Exclusion criteria included diabetes and
tobacco use within 3 months. Quantitative ultrasound scan measurements of brachial artery diameters were performed
at rest and after either forearm ischemia (ED) or administration of 0.4 mg sublingual nitroglycerin (EI). Plasma nitric
oxide (NOX = NO2 + NO3) was measured with the Saville assay. Asymmetric dimethylarginine, an endogenous inhibitor
of NOX synthase, was measured with liquid chromatography.
Results: Initial brachial artery diameters were not significantly different among the groups studied (4.85 ± 0.18 mm
for AAA group, 4.82 ± 0.17 mm for PAOD group, 4.68 ± 0.20 mm for controls). ED and EI vasodilation was signif-
icantly less (P = .02 and .03, respectively) in the AAA group (–1.71 ± 1.52 and 8.33 ± 1.13, respectively) when com-
pared with the controls (2.96 ± 1.04 and 13.88 ± 2.16, respectively). However, plasma NOX was significantly increased
(P = .01) in the AAA group (7.86 ± 0.85 µmol/L) as compared with both controls (5.13 ± 0.63 µmol/L) and PAOD
(4.85 ± 0.46 µmol/L). Asymmetric dimethylarginine levels were decreased in the AAA group (0.34 ± 0.05 µmol/L) as
compared with the PAOD group (0.46 ± 0.09 µmol/L). No correlation existed between aneurysm size and ED or EI
vasodilation or plasma NOX.
Conclusion: This study is the first to document a divergence between ED and EI vasoreactivity and systemic NO
metabolites in patients with AAAs. It is speculated that a dysfunctional vessel wall response, rather than a lack of NO,
may be important in the pathogenesis of AAAs. (J Vasc Surg 2002;35:363-7.)
tors, medical and surgical history, current medications,
and physical parameters, including body mass index and
blood pressure, were assessed. The study was approved by
the University of Michigan Institutional Review Board for
Human Subjects #1993-446.
Data collection. The patients underwent ultrasonic
evaluation of brachial artery reactivity with a well-estab-
lished methodology6 in the University of Michigan
Clinical Research Center. Brachial artery diameters at
baseline, after reactive hyperemia, and after sublingual
nitroglycerin administration exhibited no significant inter-
observer or intraobserver variation (data not shown).
Brachial artery images were obtained with a Hewlett-
Packard 10-MHz linear array transducer and an Image
Point ultrasound scan system (Hewlett Packard, Andover,
Mass). Imaging was performed with the patient resting
supine quietly for at least 10 minutes in a light-controlled
and temperature-controlled room, with electrocardio-
graphic leads placed for image capture synchronization.
After baseline measurements, a blood pressure cuff was
inflated to 200 mm Hg on the proximal right forearm for
4 minutes. The brachial artery was imaged 1 minute after
the release of the cuff. This endothelium-dependent (ED)
response was followed by a return to baseline during a
period of 15 minutes. An endothelial-independent (EI)
response then was evaluated with 0.4 mg of nitroglycerin
administered sublingually. The brachial artery images were
obtained 3 minutes after nitroglycerin administration.
After a footswitch trigger event, six sequential frames were
acquired (at a rate of 30 frames per second) through a
DT3152 video capture board (Data Translation Inc,
Marlboro, Mass) attached to a computer. This sequence
was repeated four times for a total of 24 images. The time
interval between each trigger event was left to operator
discretion. The endpoint of measurement was the percent
change in vessel diameter in response to reactive hyper-
emia or nitroglycerine administration.
The images were analyzed by the measurement of the
average vessel diameter for each image set, defined as the
distance between the intima-media interface on opposite
sides of the vessel. The flow mediated diameter ratio
(FMDR) then was calculated with the ratio of the change
in vessel diameter to the baseline diameter as defined by
the following equation, where FMDA and FMDB repre-
sent flow-mediated vessel diameters after intervention and
at baseline, respectively: FMDR = [(FMDA – FMDB)/
FMDB] × 100.
Serum collection. At the conclusion of the study, 10
mL of whole blood was collected from the patient’s con-
tralateral antecubital vein into vacutainers that contained
either ethylenediamine tetraacetic acid or heparin.
Immediately after collection, the samples were placed on
ice. The samples were centrifuged within 1 hour of collec-
tion at 1800 × g for 10 minutes at 4°C, and the plasma was
stored at –70°C until it was analyzed at a later time.
Measurement of nitric oxide. A standard colorimet-
ric assay (Cayman Chemical, Ann Arbor, Mich) was used
to measure plasma nitric oxide (NOx; nitrate and nitrite,
oxidative metabolites of endogenous NO). Briefly, nitrate
was converted to nitrite with nitrate reductase, followed
by the addition of Griess reagents, which convert nitrite to
a deep purple azo compound that is then measured spec-
trophotometrically and compared with a known standard
curve. Total plasma NOx was expressed in µmol/L.
Measurement of asymmetric dimethylarginine.
Asymmetric dimethylarginine (ADMA) was separated and
quantified with reverse-phase liquid chromatography (Waters
Xterra MS C18, 4.6 mm × 250 mm, 3.5 µm with a 3.9 mm
× 20 mm guard column at 36°C; Milford, Mass) after pre-
column fluorescent derivation (Waters AccQ•Fluor). A two-
pump gradient system (Waters HPLC, Model 510 Solvent
Delivery System) delivered 87% 10 mmol/L 4-methyl-
morphyline and 13% methanol at 1 mL/min for 65 min-
utes. Standards, blanks, and samples (10 µL) were
automatically injected (Model 712 Waters Intelligent
Sample Processor), and fluorescent peak height and area
were evaluated at an excitation of 250 nm and an emission
of 395 nm (Waters 474 Scanning Fluorescence Detector),
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Characteristics of experimental groups investigated
AAA (n = 11) PAOD (n = 9) Control (n = 10)
Age (years) 69.2 ± 2.9 67.9 ± 3.0 70.5 ± 3.1
Current tobacco use 0 (0) 0 (0) 0 (0)
History of tobacco use 10 (91%) 7 (78%) 5 (56%)
Body mass index 29.2 ± 1.2 26.2 ± 0.9 25.6 ± 1.1
Systolic BP (mm Hg) 132 ± 4 144 ± 4 129 ± 8
Diastolic BP (mm Hg) 74 ± 2 77 ± 2 74 ± 7
Myocardial infarction 5 (45%) 2 (22%) 0 (0)
Congestive heart failure 3 (27%) 1 (11%) 0 (0)
Angioplasty 3 (27%) 1 (11%) 0 (0)
CABG 4 (36%) 1 (11%) 0 (0)
CVA/TIA 2 (18%) 3 (33%) 0 (0)
Antilipidemic medications 6 (55%) 3 (33%) 1 (17%)
Antihypertensive medications 11 (100%) 6 (67%) 0 (0)
AAA, Abdominal aortic aneurysm; PAOD, peripheral arterial occlusive disease; BP, blood pressure; CABG, coronary artery bypass graft; CVA, cerebral vas-
cular accident; TIA, transient ischemic attack.
with standard curves from 10.0 µmol/L to 0.1 µmol/L
original concentrations. Only AAA (n = 5) and PAOD 
(n = 6) heparinized samples were obtained for evaluation
of ADMA levels. 
Statistical analysis. The data in this study are
reported as mean ± standard error of the mean for numer-
ical results and as group percentage for categorical results.
FMDR, NOx, and ADMA were calculated as mean ± stan-
dard error of the mean for each group. Student t test then
was applied to the numerical results, and χ2 analysis was
applied to the categorical results with a StatView software
package (SAS Inc, Cary, NC).
RESULTS
The study groups were well-matched by age, gender,
body mass index, systolic blood pressure, diastolic blood
pressure, comorbidities, and cardiovascular risk factors
(Table). Initial brachial artery diameters were nearly iden-
tical in all three groups (4.85 ± 0.18 mm for AAA, 4.82 ±
0.17 mm for PAOD, 4.68 ± 0.20 mm for control; P =
.77). No significant correlations were found between
either ED or EI vasoreactivity, NOx and age, body mass
index, or diastolic or systolic blood pressure (P > .05; data
not shown). No significant variations were observed
between initial brachial artery diameter measurements and
measurements after return to baseline after the 15-minute
rest period (P > .05 for all groups).
After reactive hyperemia, the FMDR of the AAA
group (–1.71 ± 1.52) was significantly lower (P = .02)
than that of the healthy controls (2.96 ± 1.04), and the
FMDR of the PAOD group (1.55 ± 1.31) ranged between
that of the control and the AAA groups and was not sig-
nificantly different from the AAA group or the healthy
controls (Fig 1A). After nitroglycerin administration, the
FMDR of the AAA group (8.33 ± 1.13) was significantly
lower (P = .03) than that of the healthy controls (13.88 ±
2.16). The FMDR of the PAOD group (9.47 ± 1.90)
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ranged between that of the control and the AAA groups
and was not significantly different from the AAA or con-
trol groups (Fig 1B).
Plasma NOx levels (Fig 2) in the AAA group (7.86 ±
0.85 µmol/L) were significantly increased (P = .04) as
compared with the PAOD group (4.85 ± 0.46 µmol/L)
and the control group (5.13 ± 0.63 µmol/L). No statisti-
cally significant differences between the PAOD and the
control groups were observed. Plasma ADMA levels (Fig 3)
in the AAA group (0.34 ± 0.05 µmol/L) were decreased
26% as compared with the PAOD group (0.46 ± 0.09
µmol/L), although the difference did not reach signifi-
cance (P = .30).
DISCUSSION
In this investigation, decreased vascular reactivity in
response to a normal stimulus occurred in patients with
AAAs as compared with healthy control patients. Despite
diminished vessel reactivity, systemic NO metabolites were
significantly higher in patients with AAAs. Similar findings
have been found in rabbits fed high-cholesterol diets.7
This discrepancy suggests that blood vessels in patients
with aneurysms do not respond in a normal manner to
local NO, despite being of comparable initial size to ves-
sels in healthy patients. Persistence of this effect with
nitroglycerine administration suggests that this may be a
result of a defective vessel wall, not a deficiency in endoge-
nous nitrates. The apparent decrease in ADMA, an
endogenous inhibitor of nitric oxide synthase (NOS), in
patients with aneurysms supports the tenet that the dys-
regulation of NO metabolism in the vessel wall occurs as a
systemic alteration.
Vessel wall relaxation is known to be regulated by
endothelium-derived NO by way of a cyclic guanosine
monophosphate–mediated mechanism.8-10 NG-nitro-L-
arginine methyl ester, a NOS antagonist, impairs ED
vasodilation of the brachial artery of healthy volunteers,
Fig 1. A, After reactive hyperemia, flow mediated diameter ratio (FMDR) of patients with abdominal aortic aneurysms (AAAs) was sig-
nificantly less (P = .02) than that of healthy controls. FMDR of patients with peripheral arterial occlusive disease (PAOD) was less than
that of healthy controls, but difference was not statistically significant (P = .41). B, After administration of nitroglycerine, FMDR of
patients with AAAs was significantly less (P = .03) than that of healthy controls. FMDR of patients with PAOD was less than that of
healthy controls, but difference was not statistically significant (P = .15).
A B
yet it has no effect on EI vasodilation, highlighting the
central role of NO in ED vasodilation.11
There is growing evidence that both aneurysmal and
occlusive vascular diseases are characterized by systemic
alterations in vascular reactivity.12,13 It has been previously
asserted that a reduction in iliac artery vascular reactivity
in patients with AAAs is a result of endothelial cell dys-
function caused by atherosclerotic changes in the vessel
wall.14 A major limitation of the former study was the use
of the common iliac artery to investigate systemic vascular
reactivity. The common iliac artery is commonly aneurys-
mal in patients with AAAs and therefore is not representa-
tive of healthy physiologic vascular responses in these
individuals. In addition, the former study erroneously
reported a nonsignificant decrease in EI vascular reactivity
to indicate that no impairment existed, but their study was
too underpowered (β = .19) to come to such a conclusion.
The raw data of this prior study suggest that both ED and
EI vascular reactivity are impaired in patients with AAAs.
The fact that discrepancies in vascular reactivity and NO
levels were detected in the brachial artery of patients with
AAA and PAOD in this investigation suggests that these
changes are not the result of atherosclerotic disease alone
but are likely to be multifactorial.
Possible mechanisms for elevated plasma NOx in
patients with AAAs, in view of reduced intimal and medial
reactivity, include a number of mechanisms. First, infiltra-
tion of inflammatory macrophages in the diseased vessel
wall may play a role. It is generally accepted that
aneurysms are associated with an inflammation within the
media of the vessel.15-18 As an aneurysm progresses, the
increase in leukocytes, predominantly macrophages, in this
prooxidative environment may result in significantly ele-
vated NO serum levels, despite a less responsive media. 
A second possibility would be a defect in the negative
feedback regulation of NO synthesis. Local metabolites in
regions of mild ischemia may induce increased vessel reac-
tivity through the formation of NO by vascular smooth
muscle cells, but an inability of these cells to respond to
NO in a paracrine fashion would prevent down-regulation
of NO synthesis and lead to elevated serum levels of NO.
Third, either an impairment in the incorporation of NO
into a more potent parent compound or a decreased half-
life of NO has been suggested to explain these paradoxical
findings.7 Deficiency of tetrahydrobiopterin, a cofactor of
NOS, is another possible explanation for the altered
metabolism of NO in AAAs.19 Another cofactor of NOS,
calcium-calmodulin complexes, may also be involved in
this process. Defective calcium handling by both endothe-
lial cells and smooth muscle cells would result in elevated
cytoplasmic calcium, increasing NOS activity in endothe-
lial cells and impairing vasorelaxation in vascular smooth
muscle cells. Finally, NO metabolism may also produce a
metabolite, such as S-nitroso-homocysteine, that is dam-
aging to the vasculature.20
Regardless of the cause of the elevated NO metabo-
lites, diminished vascular reactivity in patients with
aneurysms in response to systemically administered
nitrates and the paradoxical vasoconstriction in response
to reactive hyperemia suggest a desensitization of the sys-
temic vasculature to normal vasodilatory stimuli. These
stimuli, when chronic, may lead to remodeling of the arte-
rial wall, limiting the vessel responsiveness and contribut-
ing to the pathogenesis of aneurysm formation. This tenet
is further supported by the apparent decreases in levels of
ADMA in patients with aneurysms that would ordinarily
be expected to improve vascular reactivity. An impairment
of a response to NO by a dysfunctional vessel wall could
explain these findings.
The findings of this investigation appear important,
but certain study limitations must be considered in inter-
preting the data. First, the patient sample was relatively
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Fig 2. Serum nitric oxide (NOx) levels in patients with an abdom-
inal aortic aneurysm (AAA) were significantly higher than those in
healthy controls (P = .01) and in patients with peripheral arterial
occlusive disease (PAOD; P = .01). There was no significant dif-
ference in serum NOx levels between patients with PAOD and
healthy controls (P = .74).
Fig 3. Serum asymmetric dimethylarginine (ADMA) levels in
patients with an abdominal aortic aneurysm (AAA) were
decreased 26% as compared with those of patients with peripheral
arterial occlusive disease (PAOD), although this decrease was not
stastitically significant (P = .30).
small and potentially heterogeneous, especially in regards
to the incidence rate of myocardial infarction, the history
of tobacco use, and the need for antihypertensive medica-
tions. In addition, alternative methods for evaluating NO
activity, including measurements of serum platelet cyclic
guanosine monophosphate and free NO by chemilumi-
nescence, were not pursued in this study. Furthermore,
NO metabolites were not differentiated, although recent
studies have suggested that variable bioactivity exists
among these metabolites.21,22 Finally, there are several
additional soluble mediators of vascular function that may
play a role in the pathophysiology of aneurysmal disease
not assessed in this study.
A relevant issue relates to the effect of operative repair
of the AAA or occlusive disease on systemic vascular reac-
tivity. Postoperative studies might determine whether the
observed differences among the groups studied represent
a constitutional predisposition towards diminished reactiv-
ity in patients with aneurysms or whether it is simply a
result of the local aortic disease.
Despite these limitations, this investigation revealed
differences in the physiologic response of blood vessels in
patients with AAAs as compared with those with occlusive
disease and matched controls, despite increased circula-
tory serum NO metabolite levels. This paradigm sets the
stage for future investigations aimed at determining the
pathophysiologic role of NO in aneurysm initiation and
propagation. 
We thank the University Hospital’s Vascular Surgery
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